Health and Healthcare
Why Amgen Is Up Despite Falling Product Sales
Published:
Last Updated:
When Amgen Inc. (NASDAQ: AMGN) released its second-quarter financial results after the markets closed on Tuesday, the firm said that it had $3.97 in earnings per share (EPS) and $5.9 billion in revenue. That compared with consensus estimates of $3.58 in EPS and $5.66 billion in revenue, as well as the $3.83 per share on $6.06 billion posted in the same period from last year.
During the most recent quarter, revenues decreased 3% year over year, reflecting increasing competition due to patent expirations. Product sales fell 2% in the time as well.
In terms of its product sales, Amgen reported as follows:
- Prolia, $698 million
- Evenity, $28 million
- Repatha, $152 million
- Aimovig, $83 million
- Parsabiv, $168 million
- Kyprolis, $267 million
- Xgeva, $499 million
- Vectibix, $196 million
- Nplate, $201 million
- Blincyto, $78 million
- Enbrel, $1.36 billion
- Neulasta, $824 million
- Neupogen, $75 million
- Epogen, $223 million
- Aranesp, $436 million
- Sensipar/Mimpara, $122 million
Looking ahead to the full year, the company expects to see EPS in the range of $13.75 to $14.30 and revenue between $22.4 billion and $22.9 billion. Consensus estimates are calling for $13.97 in EPS and $22.59 billion in revenue for the year.
Apart from this, Amgen said that its experimental cancer drug AMG510 demonstrated activity in patients with colorectal and appendiceal cancer. Previously, the firm presented data in June suggesting AMG510 appeared to be effective against lung cancer. Amgen expects to begin a trial later this year that could serve as the basis for a U.S. regulatory application seeking approval.
Robert A. Bradway, board chair and chief executive, commented:
With our newer products generating strong volume gains globally and many first-in-class medicines advancing through our pipeline, we are well positioned to serve patients and deliver long-term growth for our shareholders.
Shares of Amgen closed Tuesday at $176.45 but traded early Wednesday at $181.88. The 52-week range is $166.30 to $210.19, and the consensus price target is $204.43.
24/7 Wall St.Is Your Money Earning the Best Possible Rate? (Sponsor)
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
